<DOC>
	<DOCNO>NCT02115035</DOCNO>
	<brief_summary>The objective evaluate overall response rate Vermurafenib administer orally patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>A Single Agent Study Evaluate Overall Response Rate , Safety Tolerability Orally Administered Vemurafenib</brief_title>
	<detailed_description>This open-label study evaluate objective response rate orally administer Vermurafenib patient double refractory multiple myeloma . Double refractory multiple myeloma myeloma become refractory two chemotherapeutic agent bortexomib lenalidomide . The study conduct two stage interim data analysis perform enrollment initial 21 subject determine whether study enroll additional 20 subject .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Been identify multiple myeloma activate NRAS , KRAS BRAF genetic mutation CD138+ cell , identify F1 test Have diagnose multiple myeloma meet three follow IMWG criterion : Clonal bone marrow plasma cell &gt; 10 % Presence serum and/or urinary Mprotein Evidence endorgan damage attribute underlying plasma cell proliferative disorder , specifically , one following : Hypercalcemia : serum calcium &gt; 11.5 mg/100 mL Renal insufficiency : serum creatinine &gt; 2 mg/dL Anemia : normochromic , normocytic hemoglobin value &gt; 2 g/100 mL low limit normal hemoglobin value &lt; 10 g/100 mL Bone lesion : lytic lesion , severe osteopenia , pathologic fracture Have measurable disease define follow : Serum Mprotein ≥1g/dL urine Mprotein ≥200 mg/24 hour protein electrophoresis If neither serum urine Mprotein meet criterion , kappa lambda serum FLC must ≥10 mg/dL accompany abnormal kappa lambda ratio ( &lt; 0.26 &gt; 1.65 ) ( Serum FLC use patient without measurable serum urine Mprotein spike . ) Have relapse refractory disease two prior multiple myeloma treatment regimen , may consist either single multiple therapy Patient must least 3 week beyond last multiple myeloma therapy previous therapy related toxicity must CTCAE ( Version 3.0 ) ≤ Grade 2 ( except alopecia ) Have Zubrod Performance Status 0 2 ( Appendix D ) Have life expectancy least 3 month opinion enrol investigator Be ≥18 year age willing provide write informed consent For woman men childbearing potential , must use effective contraceptive method previous 4 week agree continue use method study least 4 week complete study , must include two form birth control , include surgical sterilization , reliable barrier method spermicide , birth control pill , contraceptive hormone implant . Women childbearing potential must negative serum pregnancy test within 24 hour initiation VMFB therapy . Have absolute neutrophil count &gt; 1,000/mm3 Unsupported platelet count &gt; 35,000/mm3 Have total direct bilirubin &lt; 2.0 mg/dL Have aspartate aminotransferase alanine aminotransferase ≤3 time upper limit normal Have serum Creatinine ≤2.5 time upper limit normal Have hemoglobin ≥8.5 g/dL Able swallow retain orally administer medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel Have nonsecretory myeloma Have evaluable disease accord CRAB diagnostic criterion International Staging System ( ISS ) No previous history NRAS/KRAS/BRAF inhibitor Have active infection , opinion enrol investigator , serious comorbid medical condition Be receive concurrent anticancer agent therapy Be receive concurrent investigational therapy receive investigational therapy within 3 week enrollment In opinion enrol investigator , eligible receive standard therapy available know extend life expectancy Be pregnant , nursing , unwilling unable utilize two form birth control , include surgical sterilization , reliable barrier method spermicide , birth control pill , contraceptive hormone implant . Have history another malignancy , except noted Exception : Subjects diseasefree 3 year , subject history completely resect nonmelanoma skin cancer and/or subject indolent second malignancy eligible . Any serious and/or unstable preexist medical disorder ( aside malignancy exception ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure determine enrol investigator History interstitial lung disease pneumonitis . Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , excipients dimethyl sulfoxide ( DMSO ) . Any major surgery , extensive radiotherapy , chemotherapy delay toxicity , biologic therapy , immunotherapy within 21 day prior enrollment and/or daily weekly chemotherapy without potential delayed toxicity within 14 day prior enrollment . Current use prohibit medication ( Appendix F ) . History retinal vein occlusion ( RVO ) Symptomatic untreated spinal cord compression . Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence clear HBV HCV infection permit ) . History cardiovascular risk include follow : Ejection fraction ECHO MUGA must &gt; 40 % must perform within 60 day prior enrollment , unless patient receive chemotherapy within period time case LVEF must repeat New York Heart Association ( NYHA ) Class III Class IV heart failure History evidence current clinically significant uncontrolled arrhythmia . NOTE : Exception : Subjects control atrial fibrillation &gt; 30 day prior study enrollment History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior study enrollment Treatment refractory hypertension define blood pressure systolic &gt; 140 mmHg and/or diastolic &gt; 90 mm Hg control antihypertensive therapy ; Patients intracardiac defibrillator ; Known cardiac metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>